Published in final edited form as:

Bioorg Med Chem Lett. 2011 April 15; 21(8): 2341–2344. doi:10.1016/j.bmcl.2011.02.084.

Antitumor agents 287. Substituted 4-amino-2*H*-pyran-2-one (APO) analogs reveal a new scaffold from neo-tanshinlactone with in vitro anticancer activity

Yizhou Dong^a, Kyoko Nakagawa-Goto^a, Chin-Yu Lai^a, Susan L. Morris-Natschke^a, Kenneth F. Bastow, and Kuo-Hsiung Lee^{a,c,*}

^a Natural Products Research Laboratories, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599-7568

^b Division of Medicinal Chemistry and Natural Products, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599-7568

^c Chinese Medicine Research and Development Center, China Medical University and Hospital, Taichung, Taiwan

Abstract

4-Amino-2*H*-benzo[*h*]chromen-2-one (ABO) and 4-amino-7,8,9,10-tetrahydro-2*H*-benzo[*h*]chromen-2-one (ATBO) analogs were found to be significant in vitro anticancer agents in our previous research. Our continuing study has now discovered a new simplified (monocyclic rather than tricyclic) class of cytotoxic agents, 4-amino-2*H*-pyran-2-one (APO) analogs. By incorporating various substituents on the pyranone ring, we have established preliminary structure-activity relationships (SAR). Analogs **19**, **20**, **23**, and **26–30** displayed significant tumor cell growth inhibitory activity in vitro. The most active compound **27** exhibited ED₅₀ values of 0.059–0.090 μM.

Keywords

4-Amino-2*H*-pyran-2-one (APO) analogs; Neo-tanshinlactone; Cytotoxicity

In 2004, our group first isolated and synthesized neo-tanshinlactone (**1**).¹ Compound **1** was 10-fold more potent and 20-fold more selective as compared with tamoxifen citrate against the ER+ human breast cancer cell lines MCF-7 and ZR-75-1. Further structural optimization led to its 4-ethyl analog **2**, which displayed significant and selective anti-breast cancer activity both in vitro and in vivo.^{2,3} Moreover, **2** was selective for a subset of breast cancer-derived cell lines and significantly less active against normal breast-derived tissue. In order to explore the effect of individual rings on the anticancer activity, identify new lead compounds, and discover new chemical entities, we designed and reported five classes of new anticancer agents, including 2-(furan-2-yl)naphthalen-1-ol (FNO),⁴ 6-phenyl-4*H*-furo[3,2-*c*]pyran-4-one (AFPO),⁵ tetrahydronaphthalene-1-ol (TNO),⁶ 4-amino-2*H*-benzo[*h*]chromen-2-one (ABO, **3**; Figure 1),⁷ and 4-amino-7,8,9,10-tetrahydro-2*H*-

*Corresponding author. Tel: 919-962-0066; fax: 919-966-3893. khlee@unc.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

benzo[*h*]chromen-2-one (ATBO, **4**; Figure 1)⁸ analogs. Interestingly, the neotanshinlactone-inspired synthesis of a breast cancer selective ABO series was reported independently by others.⁹

Importantly, ABO and ATBO compounds displayed much higher potency than **1**-analogs, which encouraged us to further investigate these scaffolds. Structure-activity relationship (SAR) studies on **3** and **4** indicated that (1) a secondary amine (R^2 or $R^3 = H$) is preferred over tertiary amine (R^2 and $R^3 \neq H$), (2) bulky groups are favored at the R^2/R^3 position, (3) a 3'-bromophenyl group can cause a dramatic loss of potency, and (4) a non-aromatic ring-A can increase potency and cancer cell line selectivity for certain analogs. Our studies also indicated that the lactone ring-C is critical to the cytotoxic activity.^{3,7,8} Therefore, we designed a structurally simplified monocyclic scaffold (**5**, Figure 1) and incorporated various substituents at the R and R' positions to explore the contributions of ring-A and -B, develop new chemical entities and new leads, and establish the SAR. Herein, we report the design, synthesis, and biological activity of 4-amino-2*H*-pyran-2-one (APO) analogs.

As a first step in the current work, we designed two model compounds **12** and **13** by eliminating the fused ring-A/B system and incorporating pendant phenyl and styryl groups, respectively, on the remaining pyranone C-ring. 6-Substituted 4-hydroxy-2*H*-pyran-2-one **10** was synthesized according to the method reported by Bach et al.¹⁰ The appropriate aldehyde (**6**) and an acetoacetate equivalent (**7**) underwent a vinylogous Mukaiyama aldol addition to give **8**, which was oxidized to **9** using the Dess–Martin method. A thermal cyclization of **9** yielded 4-hydroxy-2*H*-pyranone **10**. Chlorination followed by amination of **10** provided model compounds **12** and **13**.⁷

Analog **12** and **13** were tested for in vitro cytotoxic activity against a panel of human tumor cell lines according to previously published methods (Table 1).³ Cell lines included A549 (non small cell lung cancer), DU145 (prostate cancer cell line), KB (nasopharyngeal carcinoma), and KB-VIN (vincristine-resistant MDR KB subline), SK-BR-3 (estrogen receptor negative, HER2 over-expressing breast cancer). Importantly, **13** showed significant inhibition of all human cancer cell lines tested with ED₅₀ values from 1.23–2.02 μM , while **12** displayed moderate activity.

Encouraged by these promising results, analogs **14–30** were designed to establish SAR correlations as well as to optimize structure and identify more active derivatives with the desired biological properties. Firstly, we installed various groups at the pyranone 6-position (R group) to explore the effect of group size, ring size, and aromaticity. Secondly, different substituents at the pyranone 4-position (R' group) were investigated while retaining the best R group. As shown in Scheme 1, new analogs **14–30** were obtained through the five-step procedure similarly to **12** and **13**, and then evaluated against five human tumor cell lines from different tissues.

Compounds **14** and **15** with methyl and isopropyl R groups were not active, and **16–18** with pentyl, cyclopentyl, and cyclohexyl groups showed moderate activity. These results suggested that long alkyl chains and cyclic alkyl groups were favored at the pyranone 6-position. Compounds **19–23**, which contain different aromatic R groups, including phenyl, styryl, benzyl, furanyl, and naphthyl, displayed significant activity. Especially, **19** and **20** with phenyl and styryl groups, respectively, were the most potent analogs with ED₅₀ values of 0.079–0.163 μM , and were equally or slightly more potent than ABO analog **3**. The results indicated that an aromatic ring at the pyranone 6-position may be critical to the cytotoxic activity.

Based on structural simplicity and chemical availability as well as the above results, we designed analogs **24–30**, which have various substituents at the pyranone 4-position and a

phenyl group fixed at the 6-position. Among them, **26–30** with substituted aniline groups displayed significant activity against all tested tumor cell lines compared with analogs containing cycloalkyl groups, including cyclohexylamine (**12**), cyclopropylamine (**24**), and piperidine (**25**). The latter two compounds totally lost cytotoxic activity. These data indicate that an aromatic amino R' group is favored at the 4-position. In addition, the position and type of substituent on the aniline ring played an important role in the cytotoxic activity. The rank order of potency for all aromatic analogs against KB was **27** (4'-Me) > **19** (4'-OMe) > **26** (H) > **28** (4'-Br) ~ **29** (2'-OMe) ~ **30** (3'-OMe). 4-Methylaniline-substituted **27** was the most potent analog with ED₅₀ values of 0.059–0.090 μM. It was about two-fold more potent than ABO analog **3**.

Overall, **19** and **27** showed greater in vitro antitumor activity than other analogs, suggesting that the combination of a phenyl group at the 6-position and a 4'-methyl- or 4'-methoxy-aniline at the 4-position is favored for the APO analogs.

In summary, we designed and developed a new class (APO) of in vitro anticancer agents, through structural simplification and optimization. Lead compounds displayed potent antitumor activity with ED₅₀ values in the low micromolar range. SAR studies indicated that: (1) an aromatic ring such as phenyl and styryl at the pyranone 6-position is critical to the antitumor activity, (2) a secondary amine at the 4-position is preferred over a tertiary amine, (3) aromatic amine groups at the 4-position are crucial, and (4) substituents on the aromatic amine group can increase potency. Compounds **19** and **27** were the most potent analogs (ED₅₀ values of 0.059–0.163 μM) among all derivatives, and thus, are new lead compounds that are promising for further development of potential clinical trials candidates.

Acknowledgments

This work was supported by NIH grant CA-17625 from the National Cancer Institute, awarded to K.H. Lee.

References and notes

1. Wang X, Bastow KF, Sun CM, Lin YL, Yu HJ, Don MJ, Wu TS, Nakamura S, Lee KH. *J Med Chem.* 2004; 47:5816. [PubMed: 15509181]
2. Wang X, Nakagawa-Goto K, Bastow KF, Don MJ, Lin YL, Wu TS, Lee KH. *J Med Chem.* 2006; 49:5631. [PubMed: 16942038]
3. Dong Y, Shi Q, Pai HC, Peng CY, Pan SL, Teng CM, Nakagawa-Goto K, Yu D, Liu YN, Wu PC, Bastow KF, Morris-Natschke SL, Brossi A, Lang JY, Hsu JL, Hung MC, Lee EY, Lee KH. *J Med Chem.* 2010; 53:2299. [PubMed: 20148565]
4. Dong Y, Shi Q, Liu YN, Wang X, Bastow KF, Lee KH. *J Med Chem.* 2009; 52:3586. [PubMed: 19425534]
5. Dong Y, Shi Q, Nakagawa-Goto K, Wu PC, Morris-Natschke SL, Brossi A, Bastow KF, Lang JY, Hung MC, Lee KH. *Bioorg Med Chem.* 2010; 8:803. [PubMed: 20034799]
6. Dong Y, Shi Q, Nakagawa-Goto K, Wu PC, Bastow KF, Morris-Natschke SL, Lee KH. *Bioorg Med Chem Lett.* 2009; 19:6289. [PubMed: 19819136]
7. Dong Y, Nakagawa-Goto K, Lai CY, Morris-Natschke SL, Bastow KF, Lee KH. *Bioorg Med Chem Lett.* 2010; 20:4085. [PubMed: 20542429]
8. Dong Y, Nakagawa-Goto K, Lai CY, Morris-Natschke SL, Bastow KF, Lee KH. *Bioorg Med Chem Lett.* 2011; 21:545.
9. Sashidhara KV, Rosaiah JN, Kumar M, Gara RK, Nayak LV, Srivastava K, Bid HK, Konwar R. *Bioorg Med Chem Lett.* 2010; 20:7127. [PubMed: 20951035]
10. Bach T, Kirsch S. *Synlett.* 2001:1974–1976.
11. Spectroscopic data. **4-(Cyclohexylamino)-6-phenyl-2H-pyran-2-one (12)**. ¹H NMR (400 MHz, DMSO-d₆): δ 7.75 (m, 2H, Ar-H), 7.39 (m, 3H, Ar-H), 6.21 (d, 1H, *J* = 2.0 Hz), 5.11 (d, 1H, *J* =

1.6 Hz, 3-*H*), 4.94 (d, 1H, *J* = 7.2 Hz, *NH*), 3.29 (m, 1H, *NCH*), 2.05 (m, 2H, *NCHCH*₂), 1.78 (m, 2H, *NCHCH*₂), 1.26 (m, 6H, cyclohexyl-*H*). MS *m/z* 270 (*M*⁺+1). **(E)-4-(Cyclohexylamino)-6-styryl-2H-pyran-2-one (13)** ¹H NMR (400 MHz, DMSO-*d*₆): δ 7.47 (m, 3H, Ar & olefin-*H*), 7.32 (m, 3H, Ar-*H*), 6.53 (d, 1H, *J* = 13.6 Hz, olefin-*H*), 5.71 (s, 1H, 3-*H*), 5.08 (d, 1H, *J* = 1.6 Hz), 4.73 (d, 1H, *J* = 7.2 Hz, *NH*), 3.27 (m, 1H, *NCH*), 2.05 (m, 2H, *NCHCH*₂), 1.78 (m, 2H, *NCHCH*₂), 1.26 (m, 6H, cyclohexyl-*H*). MS *m/z* 296 (*M*⁺+1). **4-[(4-Methoxyphenyl)amino]-6-methyl-2H-pyran-2-one (14)** ¹H NMR (400 MHz, CD₃OD): δ 7.14 (d, 2H, *J* = 8.8 Hz, Ar-*H*), 6.97 (d, 2H, *J* = 8.8 Hz, Ar-*H*), 5.97 (d, 1H, *J* = 2.0 Hz, 5-*H*), 5.14 (d, 1H, *J* = 1.6 Hz, 3-*H*), 3.82 (s, 1H, 4'-*OCH*₃), 2.20 (d, 3H, *J* = 0.8 Hz, 6-*CH*₃). MS *m/z* 230 (*M*⁺+1). **6-Isopropyl-4-[(4-methoxyphenyl)amino]-2H-pyran-2-one (15)** ¹H NMR (400 MHz, CD₃OD): δ 7.15 (d, 2H, *J* = 8.8 Hz, Ar-*H*), 6.97 (d, 2H, *J* = 8.8 Hz, Ar-*H*), 5.97 (d, 1H, *J* = 2.0 Hz, 5-*H*), 5.15 (d, 1H, *J* = 1.6 Hz, 3-*H*), 3.81 (d, 3H, *J* = 1.2 Hz, 4'-*OCH*₃), 2.72 (h, 1H, *J* = 6.8 Hz, isopropyl-*H*), 1.24 (d, 6H, *J* = 6.8 Hz, isopropyl-*H*). MS *m/z* 258 (*M*⁺+1). **4-[(4-Methoxyphenyl)amino]-6-pentyl-2H-pyran-2-one (16)** ¹H NMR (400 MHz, CD₃OD): δ 7.15 (d, 2H, *J* = 9.2 Hz, Ar-*H*), 6.97 (d, 2H, *J* = 8.8 Hz, Ar-*H*), 5.97 (d, 1H, *J* = 2.4 Hz, 5-*H*), 5.15 (d, 1H, *J* = 2.4 Hz, 3-*H*), 3.81 (s, 3H, 4'-*OCH*₃), 2.46 (t, 2H, *J* = 7.6 Hz, pentyl-*H*), 1.66 (p, 2H, *J* = 7.6 Hz, pentyl-*H*), 1.34–1.38 (m, 4H, pentyl-*H*), 0.93 (t, 3H, *J* = 7.2 Hz, pentyl-*H*). MS *m/z* 286 (*M*⁺+1). **6-Cyclopentyl-4-[(4-methoxyphenyl)amino]-2H-pyran-2-one (17)** ¹H NMR (400 MHz, CD₃OD): δ 7.14 (d, 2H, *J* = 8.8 Hz, Ar-*H*), 6.97 (d, 2H, *J* = 8.8 Hz, Ar-*H*), 5.99 (d, 1H, *J* = 2.4 Hz, 5-*H*), 5.14 (d, 1H, *J* = 2.0 Hz, 3-*H*), 3.81 (s, 3H, 4'-*OCH*₃), 2.40 (m, 1H, cyclopentyl-*H*), 2.89 (p, 1H, *J* = 8.0 Hz, cyclopentyl-*H*), 1.96–2.01 (m, 2H, cyclopentyl-*H*), 1.66–1.82 (m, 6H, cyclopentyl-*H*). MS *m/z* 284 (*M*⁺+1). **6-Cyclohexyl-4-[(4-methoxyphenyl)amino]-2H-pyran-2-one (18)** ¹H NMR (400 MHz, CD₃OD): δ 7.14 (d, 2H, *J* = 8.8 Hz, Ar-*H*), 6.97 (d, 2H, *J* = 8.8 Hz, Ar-*H*), 5.95 (s, 1H, 5-*H*), 5.15 (s, 1H, 3-*H*), 3.81 (s, 1H, 4'-*OCH*₃), 2.40 (m, 1H, cyclohexyl-*H*), 1.72–1.94 (m, 5H, cyclohexyl-*H*), 1.25–1.47 (m, 5H, cyclohexyl-*H*). MS *m/z* 298 (*M*⁺+1). **4-[(4-Methoxyphenyl)amino]-6-phenyl-2H-pyran-2-one (19)** ¹H NMR (400 MHz, CDCl₃): δ 7.82–7.85 (m, 2H, Ar-*H*), 7.48–7.51 (m, 3H, Ar-*H*), 7.20 (d, 2H, *J* = 8.8 Hz, Ar-*H*), 7.00 (d, 2H, *J* = 8.8 Hz, Ar-*H*), 6.66 (d, 1H, *J* = 2.0 Hz, 5-*H*), 5.29 (d, 1H, *J* = 2.0 Hz, 3-*H*), 3.83 (s, 3H, 4'-*OCH*₃). MS *m/z* 292 (*M*⁺+1). **(E)-4-[(4-Methoxyphenyl)amino]-6-styryl-2H-pyran-2-one (20)** ¹H NMR (400 MHz, CD₃OD): δ 7.60 (d, 2H, *J* = 7.2 Hz, Ar-*H*), 7.33–7.44 (m, 4H, Ar & olefin-*H*), 7.17–7.20 (m, 2H, Ar-*H*), 6.98–7.00 (m, 2H, Ar-*H*), 6.85 (d, 1H, *J* = 16.0 Hz, olefin-*H*), 6.20 (d, 1H, *J* = 2.0 Hz, 5-*H*), 5.25 (d, 1H, *J* = 1.6 Hz, 3-*H*), 3.82 (s, 1H, 4'-*OCH*₃). MS *m/z* 318 (*M*⁺+1). **6-Benzyl-4-[(4-methoxyphenyl)amino]-2H-pyran-2-one (21)** ¹H NMR (400 MHz, CD₃OD): δ 7.30–7.36 (m, 5H, Ar-*H*), 7.11 (d, 2H, *J* = 8.8 Hz, Ar-*H*), 6.95 (d, 2H, *J* = 9.2 Hz, Ar-*H*), 5.89 (s, 1H, 5-*H*), 5.14 (d, 1H, *J* = 1.6 Hz, 3-*H*), 3.80 (s, 3H, 4'-*OCH*₃), 3.79 (s, 2H, 6-*CH*₂). MS *m/z* 306 (*M*⁺+1). **6-(Furan-2-yl)-4-[(4-methoxyphenyl)amino]-2H-pyran-2-one (22)** ¹H NMR (400 MHz, CDCl₃): δ 7.68 (s, 1H, Ar-*H*), 7.18 (d, 2H, *J* = 8.8 Hz, Ar-*H*), 6.98–7.00 (m, 3H, Ar-*H*), 6.61–6.63 (m, 1H, Ar-*H*), 6.49 (d, 1H, *J* = 1.6 Hz, 5-*H*), 5.22 (d, 1H, *J* = 2.0 Hz, 3-*H*), 3.82 (s, 3H, 4'-*OCH*₃). MS *m/z* 282 (*M*⁺+1). **4-[(4-Methoxyphenyl)amino]-6-(naphthalen-2-yl)-2H-pyran-2-one (23)** ¹H NMR (400 MHz, CD₃OD): δ 8.42 (s, 1H, Ar-*H*), 7.86–7.99 (m, 4H, Ar-*H*), 7.57–5.59 (m, 2H, Ar-*H*), 7.23 (d, 2H, *J* = 8.8 Hz, Ar-*H*), 7.02 (d, 2H, *J* = 9.2 Hz, Ar-*H*), 6.81 (d, 1H, *J* = 2.0 Hz, 5-*H*), 5.33 (d, 1H, *J* = 2.0 Hz, 3-*H*), 3.84 (s, 3H, 4'-*OCH*₃). MS *m/z* 342 (*M*⁺+1). **4-(Cyclopropylamino)-6-phenyl-2H-pyran-2-one (24)** ¹H NMR (400 MHz, CD₃OD): δ 7.80 (m, 2H, Ar-*H*), 7.46 (m, 3H, Ar-*H*), 6.46 (s, 1H, 5-*H*), 5.41 (s, 1H, 3-*H*), 2.52 (s, 1H, 1'-*H*), 0.85 (d, 2H, *J* = 6.4 Hz, 2' & 3'-*H*), 0.58 (m, 2H, 2' & 3'-*H*). MS *m/z* 226 (*M*⁺+1). **6-Phenyl-4-(piperidin-1-yl)-2H-pyran-2-one (25)** ¹H NMR (400 MHz, CD₃OD): δ 7.89–7.92 (m, 2H, Ar-*H*), 7.47–7.49 (m, 3H, Ar-*H*), 6.92 (d, 1H, *J* = 1.6 Hz, 5-*H*), 5.28 (d, 1H, *J* = 2.0 Hz, 3-*H*), 3.57 (t, 4H, *J* = 4.8 Hz, 2' & 6'-*H*), 1.68–1.75 (m, 6H, 3', 4', & 5'-*H*). MS *m/z* (*M*⁺+1). **6-Phenyl-4-(phenylamino)-2H-pyran-2-one (26)** ¹H NMR (400 MHz, DMSO-*d*₆): δ 9.42 (s, 1H, *NH*), 7.76–7.78 (m, 2H, Ar-*H*), 7.53–7.56 (m, 3H, Ar-*H*), 7.44 (t, 2H, *J* = 7.6 Hz, Ar-*H*), 7.28 (d, 2H, *J* = 8.4 Hz, Ar-*H*), 7.21 (t, 1H, *J* = 7.2 Hz, Ar-*H*), 6.70 (d, 1H, *J* = 1.6 Hz, 5-*H*), 5.34 (t, 1H, *J* = 1.2 Hz, 3-*H*). MS *m/z* 262 (*M*⁺+1). **6-Phenyl-4-(*p*-tolylamino)-2H-pyran-2-one (27)** ¹H NMR (400 MHz, CD₃OD): δ 7.83–7.86 (m, 2H, Ar-*H*), 7.50–7.52 (m, 3H, Ar-*H*), 7.26 (d, 2H, *J* = 8.4 Hz, Ar-*H*), 7.17 (d, 2H, *J* = 8.4 Hz, Ar-*H*), 6.69 (d, 1H, *J* = 2.0 Hz, 5-*H*), 5.41 (d, 1H, *J* = 2.0 Hz, 3-*H*), 2.37 (s, 3H, *CH*₃). MS *m/z* 276 (*M*⁺+1). **4-[(4-Bromophenyl)amino]-6-phenyl-2H-pyran-2-one (28)** ¹H NMR (400 MHz, CD₃OD): δ 7.84–7.87 (m, 2H, Ar-*H*), 7.59 (d, 1H, *J* = 8.4 Hz, Ar-*H*), 7.50–7.52 (m, 3H, Ar-*H*), 7.23 (d, 1H, *J* = 8.8 Hz, Ar-*H*), 6.70 (d, 1H, *J* = 2.0 Hz, 5-*H*), 5.50 (d, 1H, *J* = 2.0 Hz, 3-*H*). MS *m/z* 340 (*M*⁺+1). **4-[(2-**

Methoxyphenylamino]-6-phenyl-2H-pyran-2-one (29) ^1H NMR (400 MHz, CD_3OD): δ 7.83–7.86 (m, 2H, Ar-*H*), 7.50–7.52 (m, 3H, Ar-*H*), 7.34 (t, 1H, $J = 8.0$ Hz, Ar-*H*), 6.81–6.89 (m, 3H, Ar-*H*), 6.71 (d, 1H, $J = 2.0$ Hz, 5-*H*), 5.53 (d, 1H, $J = 2.0$ Hz, 3-*H*), 3.82 (s, 3H, 4'- OCH_3). MS m/z 292 ($\text{M}^+ - 1$). **4-[(3-Methoxyphenylamino)-6-phenyl-2H-pyran-2-one (30)** ^1H NMR (400 MHz, CD_3OD): δ 7.83–7.86 (m, 2H, Ar-*H*), 7.50–7.52 (m, 3H, Ar-*H*), 7.34 (t, 1H, $J = 8.0$ Hz, Ar-*H*), 6.81–6.89 (m, 3H, Ar-*H*), 6.71 (d, 1H, $J = 2.0$ Hz, 5-*H*), 5.53 (d, 1H, $J = 2.0$ Hz, 3-*H*), 3.82 (s, 3H, 4'- OCH_3). MS m/z 292 ($\text{M}^+ - 1$).

Figure 1. Structures of neo-tanshinlactone (**1**), 4-ethyl neo-tanshinlactone (**2**), previously reported ABO (**3**) and ATBO (**4**) scaffolds, and newly designed APO scaffold (**5**)

Scheme 1.

Reagents and conditions: (a) TiCl_4 , CH_2Cl_2 , $-78\text{ }^\circ\text{C}$; (b) Dess-Martin reagent, rt; (c) toluene, reflux; (d) POCl_3 , Et_3N , reflux, 1h; (e) aliphatic amines, EtOH, reflux, 2h; (f) aromatic amines, ethylene glycol, $160\text{ }^\circ\text{C}$, 1h.

Table 1

Cytotoxicity of **12–30** against Human Tumor Cell Line Panel

Compd	ED ₅₀ (μM) ^a					
	KB	KB-VIN	A549	DUI45	SKBR-3	
3	0.11	0.13	0.17	0.11	0.13	
12	9.69	9.15	16.02	7.47	10.91	
13	1.25	1.24	2.02	1.23	1.53	
14	>30	>30	>30	>30	>30	
15	>30	>30	>30	>30	>30	
16	4.42	4.84	10.06	5.94	4.93	
17	5.42	4.98	8.38	5.42	4.73	
18	4.62	4.39	8.32	8.61	5.29	
19	0.093	0.098	0.16	0.12	0.079	
20	0.11	0.10	0.15	0.11	0.083	
21	1.62	1.30	2.42	1.60	1.34	
22	1.91	1.46	2.66	1.95	1.76	
23	0.15	0.13	0.18	0.15	0.13	
24	>30	>30	>30	>30	>30	
25	>30	>30	>30	>30	>30	
26	0.12	0.15	0.13	0.098	0.13	
27	0.067	0.059	0.064	0.073	0.090	
28	0.31	0.24	0.32	0.34	0.40	
29	0.44	0.49	0.35	0.37	0.54	
30	0.63	0.55	0.49	0.66	0.74	

^a mean from three or more independent tests.